Morgan Stanley Issues Pessimistic Forecast for Fractyl Health (NASDAQ:GUTS) Stock Price

Fractyl Health (NASDAQ:GUTS) had its price objective lowered by Morgan Stanley from $18.00 to $10.00 in a research note released on Monday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $1.64 on Monday. Fractyl Health has a fifty-two week low of $1.52 and a fifty-two week high of $11.55. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The firm has a market capitalization of $78.88 million and a P/E ratio of -0.13. The company’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $2.47.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. On average, equities analysts forecast that Fractyl Health will post -1.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Fractyl Health

In other news, insider Jay David Caplan sold 22,346 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. This trade represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the transaction, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $1,213,582.63. The trade was a 16.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 274,032 shares of company stock worth $602,979 over the last quarter.

Hedge Funds Weigh In On Fractyl Health

Several large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA raised its stake in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after acquiring an additional 49,289 shares during the last quarter. Geode Capital Management LLC raised its stake in Fractyl Health by 166.5% during the third quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after buying an additional 313,335 shares during the last quarter. State Street Corp raised its stake in Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after buying an additional 63,968 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after buying an additional 29,262 shares during the last quarter. Finally, Conservest Capital Advisors Inc. bought a new position in Fractyl Health during the fourth quarter worth $132,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.